The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | Findings from the Ro-CHOP trial in patients with R/R PTCL
Vincent Camus, MD, PhD, University of Rouen, Rouen, France, discusses the findings from a final analysis of the Ro-CHOP trial (NCT01796002) for the treatment of patients with relapsed/refractory (R/R) peripheral T-cell lymphoma (PTCL). While overall, there was no difference in the median progression-free survival (PFS) between the Ro-CHOP and CHOP arms, the Ro-CHOP regimen was beneficial in a subgroup of patients with follicular helper T-cell (TFH) lymphoma. Additionally, this study found that outcomes after first relapse were poor, and treatment options were very heterogeneous, with only the combination of brentuximab vedotin with chemotherapy showing improvements in PFS and overall survival (OS). This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria: Incyte, AbbVie, Astra Zeneca, BMS, Ideogen, Janssen, Kiowa Kirin, Kite/Gilead, Lilly, Novartis, Octapharma, Pfizer, Pierre Fabre, Sanofi, Takeda.
